Back
35· Cooling
Markets1h 57m ago
Glenmark Specialty S.A. has secured DCGI approval to initiate patient enrollment in India for a Phase 3 trial of Trastuzumab rezetecan (SHR-A1811) for platinum-resistant ovarian cancer.
Archive Window: 7 Days Left
India
Who
Glenmark Specialty S.A., Glenmark Pharmaceuticals, Jiangsu Hengrui Pharmaceuticals, DCGI
What
Glenmark Specialty S.A. has secured DCGI approval to initiate patient enrollment in India for a Phase 3 trial of Trastuzumab rezetecan (SHR-A1811) for platinum-resistant ovarian cancer.
When
Thu, 02 Jul 2026 03:16:20 GMT · 1h 57m ago
Where
India ·
Why
To conduct a Phase 3 trial for Trastuzumab rezetecan for platinum-resistant ovarian cancer.
The Frontline Impact
How this affects you
India becomes the first licensed market for Glenmark to begin enrollment in this Phase 3 trial. The drug, Trastuzumab rezetecan, has previously achieved regulatory milestones in China and received NMPA Breakthrough Therapy Designation for multiple indications.
Story chain
1 event in this threadNo related history yet - this is the origin event.